US Pandemic Relief Package Delivers OTC Industry Regulatory Wishes, Supplement Business Hopes
Executive Summary
It’s unlikely any industry stakeholder or FDA official expected a bill providing emergency economic relief to consumers, industries and health care services and facilities in response to a pandemic, including extensive support opportunities for small businesses, would be the vehicle that delivers on both of the industry’s congressional wishes. The supplement industry also looks for help in CARES Act.
You may also be interested in...
US Regulatory SUNSET Misses FDA’s OTC Drug Regulations, But Reaches Supplement Rules
Expiration dates in HHS’ final SUNSET rule exclude OTC drugs after CCHPA and other groups argue the rule would create more problems than it would solve. But dietary supplement regulations are subject to the rule.
US FDA’s First OTC Monograph Program User Fee Schedule Delayed For HHS Secretary’s Signature
Rates published in December for FY2021 monograph user fee program prompted immediate questions and opposition. HHS says fee schedule is being withdrawn because the document “was issued without approval of the Secretary.”
US FDA Announces OTC Monograph Drug User Fee Rates, Giving 45 Days For First Facility Payments
The FDA says the new OTC monograph drug user-fee program (OMUFA) will provide additional resources needed to support the streamlined regulatory activities described by OTC drug reform legislation enacted in March 2020.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: